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Abstract We compared the influence of exogenous N-ras onco- 
gene and treatment with PKC agonist 12-O-tetradecanoylphor- 
bol-13-acetate (TPA) on P-glycoprotein (Pgp) function in various 
human, rat and dog cell lines. Two approaches were used: (a) flow 
cytometry analysis of Rhodamine 123 (Rh123) exclusion; and 
(b) sensitivity to cytotoxic action of colchicine. We have found 
that in Ratl fibroblasts, rat IAR2 epithelial cells and rat McA 
RH 7777 (hepatoma), ras activates Pgp function, while in MDCK 
(dog kidney), K562 (human chronic myelogenous leukaemia) and 
LIM1215 (human colon carcinoma) cells it either has no effect 
or even acts in opposite direction. TPA-induced Pgp function 
shows dissimilar pattern of cell specificity. It is assumed that 
PKC and ras oncogene regulate mdr l  gene expression through 
at least partially distinct signalling pathways. 
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I. Introduction 
Acquisition of MDR in vitro and in vivo usually results from 
increased expression of the mdrl (pgyl) gene encoding so-called 
Pgp, the 170-180 kDa transmembrane glycoprotein that func- 
tions as an energy-dependent efflux pump for various lipophilic 
compounds [1-3]. A lack of response of human tumors to 
chemotherapy is often due to increased mdrl gene transcription 
[2]. The regulation of mdrl  gene activity is studied poorly. 
Recently it was shown that PKC-activating agents induce mdrl  
expression and as a result enhance Pgp function [4]. Also, it was 
found that ras oncogenes are able to activate a reporter gene 
expression driven by human mdrl gene promoter in murine 
immortalized fibroblasts [5]. However, the functional signifi- 
cance of this finding was unclear. Meanwhile an understanding 
the role of ras-mediated signalling pathway in regulation of 
mdrl  gene activity might be important for prediction of re- 
sponse to therapy with definite drugs since activation of ras 
genes is characteristic of many types of human tumors [6]. To 
study whether activated ras oncogene is really able to induce 
Pgp-mediated MDR we created the retroviral construct ex- 
pressing human N-ras a'pl2 eDNA, introduced it into various 
human and rodent cell lines and analyzed the changes in Pgp 
* Corresponding author. 
Abbreviations: MDR, multidrug resistance; FCM, flow cytometry; Pgp, 
P-glycoprotein; PKC, protein kinase C; TPA, 12-O-tetradecanoylphor- 
bol-13-acetate; PBS, phosphate-buffered saline; Rh123, Rhodamine 
123; FCS, fetal calf serum; PCR, polymerase chain reaction. 
function in the resultant cells. In addition, in order to elucidate 
whether the same signalling pathway might be responsible for 
ras- and PKC-induced MDR we compared the effects of ex- 
ogenous ras and TPA treatment in cells of different origin. 
2. Materials and methods 
2.1. Cell lines 
LIM1215 (human colon carcinoma) [7], K562 (human chronic my- 
elogenous leukaemia) [8], MDCK (dog kidney cells) [9], McA RH 7777 
(rat hepatoma) [10], IAR2 (minimally transformed rat epithelial cells) 
[1l] and Ratl (immortalized fibroblasts) were used. The cells were 
cultivated inDMEM or RPMI 1640 (for LIM 1215, K562 and McA RH 
7777) media supplemented with 10% of FCS. 
2.2. Expression vectors, isolation of cell sublines expressing exogenous 
RAS 
In order to transfer RAS oncogene into different cell lines, including 
those already expressing plasmids with neo gene, we prepared on the 
basis of pPS retroviral vector [12] the construct containing human 
activated N-ras a'p12 and selectable hygro (resistance to hygromycin) 
genes. The N-ras ~splz cDNA [13] was subcloned as BamHI-HindII! 
fragment from the pBS-ras plasmid (provided by Dr. A. Tatosyan, 
Cancer Research Center, Moscow) into appropriate cloning sites of 
pPS-3/hygro vector. The resulting construct was introduced by CaZ+P- 
transfection i to murine amphitropic packaging ~CRIP [14] cells. After 
selection with hygromycin (200/,tg/ml for three weeks) the obtained 
clones were combined and used as producers of recombinant pPS/ 
hygro-ras virions. The culture medium in which these cells (about 105 
per ml) were cultivated for one day was filtered through 0.45 /zm 
membranes (Millipore), diluted (1 : 3-1 : 5) by medium containing 1% of 
FCS and 8/zg/ml of polybrene (Serva), and added to LIM1215, K562, 
McA RH 7777, IAR2, Ratl or MDCK cells (1 ml of mixture per 105 
cells). The next day it was changed for fresh growth medium. After 
additional cultivation for 24-48 h the cells were plated 1 : 5 or 1 : 10 onto 
60 mm dishes containing selective media (hygromycin, 150 250/lg/ml). 
After 2 3 weeks with weekly medium change the resulting resistant 
cultures were trypsinised and replated. To minimise the influence of 
clonal variability we developed from all parental cell lines 1-2 inde- 
pendent sublines each derived from dozens of individual clones. 
The cultures were tested for expression of introduced N-ras by 
cDNA-PCR analysis. For this purpose total cell RNA was isolated by 
guanidine thiocyanate extraction. Synthesis of cDNA specific for re- 
combinant construct was performed on RNA template by using 24 bp 
primers that anneal just downstream of pPS/hygro cloning sites. The 
reaction mixture containing 15 pmol of primers, 1 /zg of RNA and 
5 units of TET-Z Tth DNA-polymerase (BioMaster, Moscow) in 20,ul 
of reverse transcription buffer [16.6 mM (NH4)2SO4, 67 mM tris.HCl 
pH 8.8, 1 mM MnCIz, 2.5% glycerol, 200 ,uM each of dATP, dGTP, 
dCTP and dTTP] was incubated for 15 rain at 70°C. Aliquots (2-5/A) 
from reverse transcription reaction were then used as DNA templates 
for PCR reaction using a pair of 24 bp primers pecific to the regions 
of pPS/hygro flanking cloning site. 
Changes in morphology and growth parameters ofRat 1 cell sublines 
transformed by pPS/hygro-ras were described by us earlier [15]. 
2.3. FCM analysis of Pgp function 
Evaluation of Rh123 efflux from various cells was performed ac- 
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cording to the described procedures [16,17]• The cells were detached 
from plastic, incubated with 5 mg/ml of Rh123 (Sigma) for 10 min at 
37°C, washed twice with PBS and incubated for 30 min in dye-free 
medium• The cell fluorescence was evaluated by the FACScan flow 
cytometer (Becton-Dickinson). 
2.4. Sensitivity to cytotoxic drugs 
This was determined by colony formation assay or cell counting after 
cultivation in media containing different concentrations of colchicine 
(Merck). 
3. Results and discussion 
Rat 1 cell derivatives transformed by pPS/hygro-ras construct 
showed significant increase in resistance to colchicine (Fig. 1). 
The LDs0 (drug dosage diminishing the number of clonogenic 
cells by half) for all independently selected sublines that express 
exogenous N-ras was increased 3 to 4.5-fold as compared with 
parental Rat l  or Rat/neo cells (Table 1). FCM analysis ofefflux 
of Rh123, a Pgp-transported fluorescent mitochondrial dye, 
showed that in Ratl  sublines expressing N-ras the proportion 
of Rh123-dull cells is higher than that in the parental cells. Pgp 
inhibitor verapamil abolished ras-induced stimulation of 
Rh123 efflux (Fig. 2). So, in agreement with the data showing 
activation of mdrl  gene promoter by ras oncogene [5] we ob- 
served in ras-transformed Rat 1 cell sublines timulation of Pgp 
function. However several other cell lines (MDCK dog kidney, 
K562 human myelogenous leukaemia, and LIM1215 human 
colon carcinoma cells) expressing the same pPS/hygro-ras 
retroviral construct showed neither decreased colchicine sensi- 
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Fig. I. Influence of expression of exogenous N-ras "sN2 on sensitivity of
various cell lines to colchicine. Cell survival was estimated as a ratio 
of a number of colonies (for Ratl sublines) or cells (for K562 and 
LIM1215 sublines) grown at given colchicine dosage to those grown in 
drug-free medium. For clonogenic assay 3 x 102 cells were seeded in 
duplicate onto 60 mm dishes for 14 days. In cell yield assay 5 × 104 cells 
were plated into 25 cm 2 flasks for 7 days• For each pair of cell sublines 
the data of one of typical experiments are presented. 
tivity, nor enhanced Rh123 exclusion (Figs. 1,2; Table 1). 
Meanwhile, according to the data of cDNA-PCR analysis (Fig. 
3) the levels of exogenous ras mRNA in these cells were compa- 
rable with those found in rat cell lines showing either pro- 
nounced (Rat/neo fibroblasts; IAR2 rat epithelial cells) or 
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Fig. 2. Effects of N-ras oncogene on Pgp activity in Rat 1, M DCK, and IAR2 cells• Logarithmic fluorescence intensity of ras-expressing and parental 
was studied after staining with Rh123 as described in section 2. N-ras stimulated Rh123 efflux in Rat/neo-ras2 and IAR2-ras/C5 cells, while in 
MDCK-ras/A4 its expression was accompanied by some inhibition of Pgp activity• Incubation in the presence of 30 mM of verapamil (the lower 
row) caused complete reversion of ras-induced activation of Pgp function in Rat I and IAR2 cell derivatives whereas in MDCK-ras/A4 cells it did 
not influence Rh123 efflux. 
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Fig. 3. cDNA-PCR analysis of cell sublines developed as a result of 
retrovirus mediated transfer of pPS/hygro-ras construct, cDNAs spe- 
cific for mRNAs produced by exogenous constructs were synthesized 
and amplified as described in section 2, separated on l% agarose gel 
and visualized by ethidium bromide staining. In all the sublines elected 
with hygromycin after introduction of pPS/hygro-ras (tracks 1-3, 7 10 
K562-ras, IAR2-ras/F10, LIM1215-rasl, MDCK-ras/B2, IAR2-ras/ 
C5, MDCK-ras/C4, and Rat/neo-rasl, respectively) the fragment of 
expected molecular weight (about 900 bp) is seen (arrow). In Rat/hygro 
cells (track 6) infected with insert-free pPS/hygro construct a low- 
molecular weight fragment (about 300 bp) corresponding to the vector 
adapter egion was amplified. Parental K562 (track 4) and LIM1215 
(track 5) do not show the pPS-specific amplification products. Left the 
position of the marker fragments i indicated. 
slight (McA RH 7777 rat hepatoma) induction of Pgp function 
(Table 1). Such differences in activation of Pgp function may 
reflect either species-specific (rodent vs. dog and human),  or 
tissue-specific distinctions in response to ras oncogene. In pre- 
vious studies cell-specific st imulation of mdr l  gene expression 
was observed after treatment with cytotoxic drugs [18] and 
PKC agonists [4]. Interestingly that while the former study 
Table 1 
Cell-specific induction of P-glycoprotein-mediated MDR by activated 
N-ras oncogene 
Cells pPS/hygro-ras Relative Rh123 
expression drug-resistance* exclusion 
Ratl - 1 .0  + 
Rat/ras + 3.1 +++ 
Rat/neo - 1.0  + 
Rat/neo-rasl + 4.5 ++++ 
Rat/neo-ras2 + 4.0 ++++ 
IAR2 - 1.0 + 
IAR2-ras/C5 + n.d. +++ 
McA RH 7777 - 1.0 + 
McA RH 7777-ras2 + 2.1 ++ 
MDCK - 1.0 + 
MDCK-ras/B2 + n.d. - 
MDCK-ras/A4 + n.d. - 
K562 - 1.0 + 
K562-ras + 0.7 - 
LIM1215 - 1.0 + 
LIMl215-rasl + 0.8 - 
LIM 1215-ras2 + 0.8 - 
*Relation of LDs0 of colchicine for given cell subline to LDs0 for 
parental cells. 
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Fig. 4. Differential effects of TPA and activated RAS on Pgp activity 
in Ratl and MDCK cells. Unlike N-ras asps2 TPA stimulates Rh123 
efflux in MDCK but not in Rat/neo cells where it causes light inhibi- 
tion of Pgp function. 
revealed some distinctions between human and rodent cells, the 
latter observed ifferences in mdr l  gene response in various cell 
lines of human origin. The results obtained to date are insuffi- 
cient to understand the basis of differential susceptibility of 
various cell lines to ras-mediated stimulation of Pgp activity. 
However they indicate that ras gene mutat ions may have differ- 
ent prognostic significance in prediction of response to chemo- 
therapy of various types of human tumors. 
In cells transformed by ras oncogenes activation of PKC is 
often observed [19]. To elucidate whether the same signalling 
pathway might be responsible for ras- and PKC-induced activa- 
t ion of mdr l  gene we compared the effects of exogenous N- 
ras "Sp~2 and TPA (an efficient activator of PKC) on Pgp func- 
t ion in a variety of cell types. We found that majority of cell 
lines tested showed differential sensitivity to Pgp-related effects 
of ras and TPA. For example, expression of N-ras aspl2 in 
MDCK cells causes no increase in Pgp function (Fig. 2) while 
treatment of MDCK cells with TPA increases the proport ion 
of Rh123-dull cells (Fig. 4). Differential response of Pgp-medi- 
ated Rh123 efflux to ras and TPA was observed also in Rat l  
and L IMI215 cell lines (Figs. 2,4; Table 2). These findings 
suggest hat ras oncogenes and PKC probably regulate mdr l  
gene expression through different (at least in part) signalling 
pathways. The detailed mechanisms of such regulation are a 
subject for future studies. 
Table 2 
Comparison of the effects of exogenous N-ras oncogene and TPA in 
various cell lines 
Cell line Stimulation of Rh123 efflux 
N-ras TPA 
Rat/neo ++++ - 
McA RH 7777 + ++ 
MDCK - + 
LIM1215 - + 
376 T.P Stromskaya et al./FEBS Letters 368 (1995) 373376 
Acknowledgements: Wethank Dr. T. Zabotina (Cancer Research Cen- 
ter, Moscow) and Dr. A. Poletaev (Engelhardt Institute of Molecular 
Biology, Moscow) for help in FCM analysis of Rh 123 efflux. This work 
was supported in part by grants from the Russian Fund for Basic 
Research and the International Science Foundation. 
References 
[1] Endicott, J.A. and Ling, V. (1989) Annu. Rev. Biochem. 58, 137 
171. 
[2] Roninson, I.B. (1992) Biochem. Pharmacol. 43, 95-102. 
[3] Chin, K.-V., Pastan, I. and Gottesman, M.M. (1993) Adv. Cancer 
Res. 60, 157 180. 
[4] Chaudhary, P.M. and Roninson, I.B. (1992) Oncol. Res. 4, 281 
290. 
[5] Chin, K.-V., Ueda, K., Pastan, I. and Gottesman, M.M. (1992) 
Science 255, 459462. 
[6] Bos, J.L. (1989) Cancer Res. 49, 4682-4689. 
[7] Whitehead, R.H., Macrae, F.A., St. John, D.J.B. and Ma, J. (1985) 
J. Natl. Cancer Res. 74, 75%765. 
[8] Lozzio, C.B. and Lozzio, R.B. (1975) Blood 45, 321-334. 
[9] Lever, J. (1979) Proc. Natl. Acad. Sci. USA 76, 1323-1327. 
[10] Becker, J., De Nechaud, B. and Potter, V.E (1976) in: Onco- 
Developmental Gene Expression (Fisfman, W.H., Sell, S., Eds.) 
NY, Academic Press, pp. 259-270. 
[11] Montesano, R., Saint Vincent, L., Drevon, C. and Tomatis, L. 
(1975) Int. J. Cancer 16, 550-558. 
[12] Prassolov, V.S. and Chumakov, P.M. (1988) Mol. Biol. 22, 1371- 
1380 (in Russian). 
[13] Souyri, M., Koehne, C.F., O'Donnel, EV., Aldrich, T.H., Furth, 
M.E. and Fleissner, E. (1987) Virology 158, 6%78. 
[14] Danos, O. and Mulligan, R.C. (1988) Proc. Natl. Acad. Sci. USA 
85, 6460 6464. 
[15] Khramtsova, S., Stromskaya, T., Potapova, G., Chumakov, P. 
and Kopnin, B. (1993) Biochem. Biophys. Res. Commun. 194, 
383 390. 
[16] Neyfakh, A.A. (1988) Exp. Cell. Res. 174, 168-176. 
[17] Chaudhary, P.M. and Roninson I.B. (1991) Cell 66, 85-94. 
[18] Chin, K.-V., Chauhan, S.S., Pastan, I. and Gottesman, M.M. 
(1990) Cell Growth Diff. 1,361-365. 
[19] Weinstein, I.B., Borner, C.M., Krauss, R.S., O'Driscoll, K., Choi, 
P.M., Moritomi, M., Hoshina, S., Hsieh, L.-L., Tshou-Wong, 
K.-M., Guadagno, S.N., Ueffing, M. and Guillem, J. (1991) in: 
Origins of Human Cancer: A Comprehensive R view (Brugge, J., 
Curran, T., Harlow, E. and McCormick, F., Eds.) Cold Spring 
Harbor, Cold Spring Harbor Laboratory Press, pp. 113-124. 
